Adjuvant Chemoradiotherapy and Interferon Alfa in Treating Patients With Resected Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

March 31, 2003

Primary Completion Date

July 31, 2007

Study Completion Date

February 28, 2011

Conditions
Pancreatic Cancer
Interventions
BIOLOGICAL

interferon-alfa-2b

IV

DRUG

cisplatin

IV

DRUG

5-fluorouracil

IV

RADIATION

radiation therapy

Trial Locations (14)

10021

Memorial Sloan-Kettering Cancer Center, New York

14642

James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester

37232

Vanderbilt-Ingram Cancer Center, Nashville

40202

James Graham Brown Cancer Center at University of Louisville, Louisville

53226

Medical College of Wisconsin Cancer Center, Milwaukee

55455

Fairview University Medical Center - University Campus, Minneapolis

60612

Rush University Medical Center, Chicago

75231

Presbyterian Hospital of Dallas, Dallas

77030

Baylor University Medical Center - Houston, Houston

32610-0232

University of Florida Shands Cancer Center, Gainesville

02114

Massachusetts General Hospital Cancer Center, Boston

02115

Brigham and Women's Hospital, Boston

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston

14263-0001

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Alliance for Clinical Trials in Oncology

OTHER

NCT00059826 - Adjuvant Chemoradiotherapy and Interferon Alfa in Treating Patients With Resected Pancreatic Cancer | Biotech Hunter | Biotech Hunter